SS Innovations International (SSII)
Builds surgical robotics around the SSi Mantra platform.
Something off on this page? Send us feedback.
Sells the SSi Mantra surgical robotic system and SSi Mudra instruments. The India-based operating business, founded in 2019, became the core of the current Nasdaq-listed issuer through the CardioVentures merger.
SSi Mantra surgical robotic system and SSi Mudra instruments form the commercial offering of an India-based surgical-robotics business founded in 2019. Commercial sales began after the system's introduction, and the platform supports multiple surgical specialties.
R&D, manufacturing, assembly, and operations are concentrated in the Gurgaon/Delhi NCR area. The company states an affordability-and-accessibility objective for advanced surgical robotics.
The Florida-listed issuer took its current form through the CardioVentures merger and began Nasdaq trading as SSII in April 2025. Its listed identity reflects a merger-driven transition rather than a long-running U.S. medtech lineage.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $13.6M · Total debt $3.2M · Total assets $97.0M · Shareholders' equity $53.4M
- Revenue
- $13.9M
- Operating income
- −$2.3M
- Net income
- −$2.7M
No dividends on record.
| Institutions | 0.82% | 1.64M shares | |
|---|---|---|---|
| 23 holders · as of Jun 30, 2026 | |||
| Insiders | 81.44% | 163.20M shares | |
| 9 holders · as of Sep 9, 2026 | |||
| Other | 17.74% | 35.54M shares | |
| remainder | |||
200.39M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Srivastava SudhirInsiderdirector, 10 percent owner, officer: Chairman and CEO | 54.16% | 108.52M | filed Sep 9, 2026 |
Frederic H. Moll1Insiderdirector, 10 percent owner | 11.13% | 21.79M | filed Mar 10, 2026 |
Ranjan R. PaiInsider | 7.46% | 14.95M | filed Feb 12, 2025 |
Barry F. CohenInsiderdirector, officer: COO - Americas | 3.87% | 7.76M | filed Jun 2, 2026 |
Timothy P. AdamsInsiderdirector | 2.66% | 5.33M | filed Mar 10, 2026 |
- Frederic H. Moll's transaction reports restate only vehicles that traded; the 2025 ownership statement (21.79M) plus the 501.3K net shares acquired since is used instead.
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Sep 4, 2026 | Srivastava Sudhir | director, 10 percent owner, officer: Chairman and CEO | −33,333 | $3.00 |
| Mar 6, 2026 | Srivastava Sudhir | director, 10 percent owner, officer: Chairman and CEO | +498,753 | $4.01 |
| Mar 6, 2026 | Timothy P. Adams | director | +300,000 | $3.99 |
| Mar 6, 2026 | Frederic H. Moll | director, 10 percent owner: | +501,253 | $3.99 |
- Intuitive Surgical
da Vinci platforms span the same multi-specialty soft-tissue surgery.
- Medtronic
Hugo RAS extends into urologic, general, and gynecologic surgery.
- Johnson & Johnson
OTTAVA targets multi-specialty soft-tissue and upper-abdominal surgery.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| SS Innovations International | $3.18 | −3.64% | $660.4M | — | — | 12.6 | +39.4% |
| Intuitive Surgical | $399.90 | −0.54% | $142.05B | 45.7 | 35.3 | 12.9 | +18.5% |
| Medtronic | $90.64 | −0.14% | $116.19B | 22.4 | 15.1 | 3.1 | +13.7% |
| Johnson & Johnson | $270.17 | +0.36% | $648.72B | 31.2 | 22.8 | 6.6 | +6.6% |
| Median | 31.2 | 22.8 | 6.6 | +13.7% |